


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A tetrahydroquinoline derivative according to Formula 1,



Formula I

or a pharmaceutically acceptable salt thereof, wherein

R¹ and R² are H or Me

R³ is H, hydroxy, (1-4C)alkoxy, ~~(di)(1-4C)alkylamino(2-4C)alkoxy or (2-6)heterocycloalkyl(2-4C)alkoxy~~

R⁴ is H, OH, or (1-4C)alkoxy ~~or R⁷~~

R⁵ is ~~H~~, OH, (1-4C)alkoxy or R⁷

with the proviso that if R⁴ is H, R⁵ is not ~~H~~, OH or (1-4C)alkoxy ~~and that if R⁵ is H, R⁴ is not H, OH or (1-4C)alkoxy~~

R⁶ is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, ~~(2-6C)heterocycloalkyl~~ or (1-6C)alkyl, wherein the (2-5C)heteroaryl and the (6C)aryl are optionally substituted with one or more substituents selected from hydroxyl, amino, halogen, nitro, phenyl, (1-4C)alkyl, (1-4C)alkoxy, or (1-4C)(di)alkylamino

R^7 is amino, (di)(1-4C)alkylamino, ~~(6C)arylcarbonylamino,~~
~~(6C)arylcarbonyloxy,~~ (2-5C)heteroarylcarbonylamino, (2-5C)heteroarylcarbonyloxy, R^8 -
~~(2-4C)alkylamino,~~ R^8 -(2-4C)alkoxy, R^9 -methylamino or R^9 -methoxy

R^8 is hydroxy, amino, (1-4C)alkoxy, (di)(1-4C)alkylamino, (2-
6C)heterocycloalkyl, (2-6C)heterocycloalkylcarbonylamino, ~~(di)(1-
4C)alkylaminocarbonylamino,~~ or (1-4C)alkoxycarbonylamino and

R^9 is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (2-5C)heteroaryl,
optionally substituted with one or more (1-4C)alkyl substituents, or (6C)aryl.

2. (Cancelled).
3. (Cancelled).
4. (Currently Amended) The tetrahydroquinoline derivative of claim ~~3~~ 1 wherein R^8 is amino, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl or (2-6C)heterocycloalkylcarbonylamino.
5. (Currently Amended) The tetrahydroquinoline derivative of claim ~~2~~ 1 wherein R^7 is (di)(1-4C)alkylamino, R^8 -(2-4C)alkoxy, R^9 -methylamino or R^9 -methoxy.
6. (Previously presented) The tetrahydroquinoline derivative of claim 5 wherein R^8 is amino, (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
7. (Previously presented) The tetrahydroquinoline derivative of claim 6 wherein R^8 is (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
8. (Cancelled).
9. (Currently Amended) The tetrahydroquinoline derivative of claim ~~8~~ 5 wherein R^6 is (2-5C)heteroaryl or (6C)aryl.

10. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R⁶ is (4-5C)heteroaryl or (6C)aryl and R⁹ is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

11. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R⁷ is (di)(1-4C)alkylamino, R⁸-ethoxy, R⁹-methylamino or R⁹-methoxy and R⁹ is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

12. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R⁸ is (di)(1-4C)alkylamino or (4-5C)heterocycloalkyl and R⁹ is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

13. (Previously presented) A pharmaceutical composition comprising the tetrahydroquinoline derivative of claim 1 and at least one pharmaceutically suitable auxiliary.

14. (Cancelled)

15. (Cancelled)

16. (Previously presented) A method of fertility regulation comprising administering an FSH receptor activity modulating amount of the pharmaceutical composition of claim 13.